TY - JOUR
T1 - Deficiency in the phosphatase PHLPP1 suppresses osteoclast-mediated bone resorption and enhances bone formation in mice
AU - Mattson, Anna M.
AU - Begun, Dana L.
AU - Molstad, David H.H.
AU - Meyer, Margaret A.
AU - Oursler, Merry Jo
AU - Westendorf, Jennifer J.
AU - Bradley, Elizabeth W.
N1 - Funding Information:
This work supported by National Institutes of Health Research Grants AR065397, AR072634, AR068103, AR065402, and AR067129, the Mayo Clinic Center for Biomedical Discovery, and the Mayo Clinic Foundation. The authors declare that they have no conflicts of interest with the con-tents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Insti-tutes of Health.
Funding Information:
This work supported by National Institutes of Health Research Grants AR065397, AR072634, AR068103, AR065402, and AR067129, the Mayo Clinic Center for Biomedical Discovery, and the Mayo Clinic Foundation. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019 Mattson et al.
PY - 2019/8/2
Y1 - 2019/8/2
N2 - Enhanced osteoclast-mediated bone resorption and diminished formation May promote bone loss. Pleckstrin homology (PH) domain and leucine-rich repeat protein phosphatase 1 (Phlpp1) regulates protein kinase C (PKC) and other proteins in the control of bone mass. Germline Phlpp1 deficiency reduces bone volume, but the mechanisms remain unknown. Here, we found that conditional Phlpp1 deletion in murine osteoclasts increases their numbers, but also enhances bone mass. Despite elevating osteoclasts, Phlpp1 deficiency did not increase serum markers of bone resorption, but elevated serum markers of bone formation. These results suggest that Phlpp1 suppresses osteoclast formation and production of paracrine factors controlling osteoblast activity. Phlpp1 deficiency elevated osteoclast numbers and size in ex vivo osteoclastogenesis assays, accompanied by enhanced expression of proto-oncogene C-Fms (C-Fms) and hyper-responsiveness to macrophage colony-stimulating factor (M-CSF) in bone marrow macrophages. Although Phlpp1 deficiency increased TRAP cell numbers, it suppressed actin-ring formation and bone resorption in these assays. We observed that Phlpp1 deficiency increases activity of PKC, a PKC isoform controlling cell polarity, and that addition of a PKC pseudosubstrate restores osteoclastogenesis and bone resorption of Phlpp1-deficient osteoclasts. Moreover, Phlpp1 deficiency increased expression of the bone-coupling factor collagen triple helix repeat-containing 1 (Cthrc1). Conditioned growth medium derived from Phlpp1-deficient osteoclasts enhanced mineralization of ex vivo osteoblast cultures, an effect that was abrogated by Cthrc1 knockdown. In summary, Phlpp1 critically regulates osteoclast numbers, and Phlpp1 deficiency enhances bone mass despite higher osteoclast numbers because it apparently disrupts PKC activity, cell polarity, and bone resorption and increases secretion of bone-forming Cthrc1.
AB - Enhanced osteoclast-mediated bone resorption and diminished formation May promote bone loss. Pleckstrin homology (PH) domain and leucine-rich repeat protein phosphatase 1 (Phlpp1) regulates protein kinase C (PKC) and other proteins in the control of bone mass. Germline Phlpp1 deficiency reduces bone volume, but the mechanisms remain unknown. Here, we found that conditional Phlpp1 deletion in murine osteoclasts increases their numbers, but also enhances bone mass. Despite elevating osteoclasts, Phlpp1 deficiency did not increase serum markers of bone resorption, but elevated serum markers of bone formation. These results suggest that Phlpp1 suppresses osteoclast formation and production of paracrine factors controlling osteoblast activity. Phlpp1 deficiency elevated osteoclast numbers and size in ex vivo osteoclastogenesis assays, accompanied by enhanced expression of proto-oncogene C-Fms (C-Fms) and hyper-responsiveness to macrophage colony-stimulating factor (M-CSF) in bone marrow macrophages. Although Phlpp1 deficiency increased TRAP cell numbers, it suppressed actin-ring formation and bone resorption in these assays. We observed that Phlpp1 deficiency increases activity of PKC, a PKC isoform controlling cell polarity, and that addition of a PKC pseudosubstrate restores osteoclastogenesis and bone resorption of Phlpp1-deficient osteoclasts. Moreover, Phlpp1 deficiency increased expression of the bone-coupling factor collagen triple helix repeat-containing 1 (Cthrc1). Conditioned growth medium derived from Phlpp1-deficient osteoclasts enhanced mineralization of ex vivo osteoblast cultures, an effect that was abrogated by Cthrc1 knockdown. In summary, Phlpp1 critically regulates osteoclast numbers, and Phlpp1 deficiency enhances bone mass despite higher osteoclast numbers because it apparently disrupts PKC activity, cell polarity, and bone resorption and increases secretion of bone-forming Cthrc1.
UR - http://www.scopus.com/inward/record.url?scp=85070764319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070764319&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA119.007660
DO - 10.1074/jbc.RA119.007660
M3 - Article
C2 - 31189651
AN - SCOPUS:85070764319
SN - 0021-9258
VL - 294
SP - 11772
EP - 11784
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 31
ER -